Article Text

Download PDFPDF

OP0252 Organ damage progression and long-term safety of belimumab (BEL) in patients with systemic lupus erythematosus (SLE): an extension of pivotal phase 3 bliss studies
  1. R.F. Van Vollenhoven1,
  2. S.V. Navarra2,
  3. R.A. Levy3,
  4. M. Thomas4,
  5. A. Heath3,
  6. T. Lustine3,
  7. A. Adamkovic3,
  8. J. Fettiplace5,
  9. M.L. Wang3,
  10. B. Ji5,
  11. D. Roth3
  1. 1Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
  2. 2University of Santo Tomas Hospital, Manila, Philippines
  3. 3GSK, Collegeville, PA, USA
  4. 4Kerala Institute of Medical Sciences, Trivandrum, Kerala, India
  5. 5GSK, Stockley Park, UK


Background Non-United States completers of the Phase 3 BLISS-52 (BEL110752) and BLISS-76 (BEL110751) studies could continue treatment with BEL.

Objectives To evaluate long-term safety, tolerability and organ damage progression in patients with SLE treated with BEL.

Methods In this multicentre, open-label long-term study (BEL112234/NCT00712933), patients received intravenous BEL every 4 weeks, plus standard SLE therapy. Safety was assessed at each visit. Organ damage (Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index [SDI]) was assessed as a safety endpoint every 48 weeks. The study continued until BEL was commercially available in each patient’s country and included an 8 week follow–up period.

Results In total, 738 patients entered the long-term study and were treated for up to 9 years (3352 patient-years). Of these, 735 (99.6%) received ≥1 dose of BEL; the mean (SD) number of infusions was 56.4 (27.02). The incidence of adverse events (AEs) remained stable or declined over time (table 1). The most common AEs were headache (n=205, 27.9%), nasopharyngitis (n=155, 21.1%), diarrhoea (n=143, 19.5%), arthralgia (n=136, 18.5%) and influenza (n=134, 18.2%). Sixty-nine patients (9.4%) experienced an AE resulting in discontinuation of BEL or study withdrawal. Eleven deaths occurred, one of which (cardiogenic shock) was possibly related to BEL. Three serious AEs of suicide attempt/ideation (0.4%) occurred. The mean (SD) SDI score was 0.6 (1.02) at baseline (prior to the first dose of BEL). At Year 8 87.7% of patients had no change in SDI score from baseline, indicating low organ damage accrual (figure 1).

aNumber of patients; bincluded opportunistic infections, tuberculosis, herpes zoster (recurrent and disseminated) and sepsis; ctwo deaths during post-treatment follow-up.

Conclusions BEL displayed a stable safety profile with no new safety signals. There was minimal organ damage progression.

Acknowledgements Study funded by GSK. Emma Hargreaves, MA, Fishawack Indicia Ltd, UK, provided editorial assistance funded by GSK.

Disclosure of Interest R. Van Vollenhoven Grant/research support from: GSK, Consultant for: GSK, S. Navarra Speakers bureau: GSK, R. Levy Employee of: BLISS-52 investigator and GSK employee since ,Jan 2018 M. Thomas Grant/research support from: GSK, Consultant for: GSK, A. Heath Shareholder of: GSK, Employee of: GSK, T. Lustine Shareholder of: GSK, Employee of: GSK, A. Adamkovic Shareholder of: GSK, Employee of: GSK, J. Fettiplace Shareholder of: GSK, Employee of: GSK (at the time of study), M. L. Wang Shareholder of: GSK, Employee of: GSK, B. Ji Shareholder of: GSK, Employee of: GSK, D. Roth Shareholder of: GSK, Employee of: GSK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.